Klin Farmakol Farm. 2012;26(4):166-170

Drug-induced renal injury with regard to non-steroidal anti-inflammatory drugs

Zoltán Varga, Milan Kriška, Veronika Slezáková
Ústav farmakológie a klinickej farmakológie, Lekárska fakulta Univerzity Komenského v Bratislave

Drug-induced renal injury represents a frequently discussed, yet, in clinical medicine, often underestimated problem. Physicians of various

specializations encounter adverse drug reactions affecting the kidneys. The importance of the issue is underlined by the high number of

drugs with nephrotoxic potential. Non-steroidal anti-inflammatory drugs are among the most prescribed drug groups worldwide, with

numerous preparations being available over the counter. Active substances belonging to this group have non-negligible potential to cause

drug-induced renal injury. The risk is accentuated in the case of concomitant use of other drugs capable of inducing a worsening of kidney

function. The presence of dehydration and diseases affecting the kidneys further increase the likelihood of drug-induced damage. Adequate

awareness among patients and healthcare professionals of this risk and the possible ways of its reduction is assumed to have considerable

potential to reduce the incidence of adverse drug reactions. The present paper aims to highlight the risk of drug-induced renal injury during

pharmacotherapy with an emphasis on non-steroidal anti-inflammatory drugs. The purpose is to raise the awareness of the importance

of taking into account the renal risk when prescribing a drug and educating patients while handing them an over-the-counter medication.

Keywords: drug-induced renal injury, non-steroidal anti-inflammatory drugs, adverse effect, kidney failure, nephrotoxicity

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varga Z, Kriška M, Slezáková V. Drug-induced renal injury with regard to non-steroidal anti-inflammatory drugs. Klin Farmakol Farm. 2012;26(4):166-170.
Download citation

References

  1. Bach PH, Bonner FW, Bridges JW, Lock EA (Eds.). Nephrotoxicity: Assesment and Pathogenesis. Chichester; Willey, 1982: 554.
  2. Rossert J. Drug-induced acute interstitial nephritis. Kidney international 2001; 60: 804-817. Go to original source... Go to PubMed...
  3. Hegyi L, Krajčík Š (Eds.). Geriatria pre praktického lekára. 1. vyd. Bratislava; HERBA, 2004: 298.
  4. Stollberger C, Finsterer J. Did thirst-blockers like angiotensin-converting-enzyme inhibitors, sartans, serotonine-re-uptake inhibitors, dopamine agonists/antagonists, or atypical neuroleptics contribute to the exorbitant number of fatalities during the French 2003 heat wave? Pharmacoepidemiol Drug Saf 2007; 16: 1252-1253. Go to original source... Go to PubMed...
  5. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19. Go to original source... Go to PubMed...
  6. Aronson JK (Ed.). Meyler´s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. Amsterdam; Elsevier, 2006: 4192.
  7. Baxter K (Ed). Stockley´s drug interactions (ninth edition). London; Pharmaceutical Press, 2010: 1792.
  8. Davies DM (Ed.). Textbook of adverse drug reactions. Fourth edition. Oxford; Oxford University Press, 1991: 879.
  9. Krajčík Š, Tatranská T, Gadušová M, Mikuš P. Iatrogénne poškodenie obličiek u starších ľudí. Geriatria 2011; 11(3): 125-132.
  10. Michenot F, Sommet A, Bagheri H, Lapeyre-Mestre M, Montastruc JL. Adverese drug reactions in patients older than 70 years during the heat wave occured in France in summer 2003: a study from the French pharmacovigilance database. Pharmacoepidemiol Drug Saf 2006; 15(10): 735-740. Go to original source... Go to PubMed...
  11. Simmons LD, Botting MR, Hla T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56(03): 387-437. Go to original source... Go to PubMed...
  12. Osborn JL, Kopp UC, Thames MD, DiBona GF. Interactions among renal nerves, prostaglandins, and renal arterial pressure in the regulation of renin release. Am J Physiol 1984; 247(5): 706-713. Go to original source... Go to PubMed...
  13. Catella-Lawson F, McAdam B, Morrison B, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289(2): 735-741. Go to PubMed...
  14. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX) -2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of cox-inhibiting therapies (Select) trial in osteoarthritis. Brit J Rheumatol 1998; 37(9): 946-951. Go to original source... Go to PubMed...
  15. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoartfritis pacients. Brit J Rheumatol 1998; 37(9): 937-945. Go to original source... Go to PubMed...
  16. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Int Med 2000; 160: 1465-1470. Go to original source... Go to PubMed...
  17. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low salt diet. Ann Intern Med 2000; 133: 1-9. Go to original source... Go to PubMed...
  18. Whelton A, Maurath CL, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7: 159-175. Go to original source... Go to PubMed...
  19. Pairet M, VanRyn J (Eds). COX-2 Inhibitors. Basel-Boston-Berlin; Birkhäuser, 2004: 249. Go to original source...
  20. Antillon M, Cominelli F, Lo S, et al. Effects of oral prostaglandins on indomethacin induced renal failure in patients with cirrhosis and ascites. J Rheumatol Suppl 1990; 20: 46-49. Go to PubMed...
  21. Murray MD, Brater DC, Tierney WM. Ibuprofen-associated renal impairment in a large general internal medicine practice. Am J Med Sci 1990; 299(4): 222-229. Go to original source... Go to PubMed...
  22. Walter AN, Lenz TL. Hydratation and medication use. Am J Lifestyle Med 2011; 5(4): 332-335. Go to original source...
  23. Gorski T, Cadore EL, Pinto SS, et al. Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use. Br J Sports Med 2011; 45: 85-90. Go to original source... Go to PubMed...
  24. Hudec R, Božeková L, Kriška M, Kořínková V, Magálová T. Nežiaduci účinok lieku a jeho hodnotenie. Klin Farmakol Farm. 2006; 20(4): 223-225.
  25. Douthwaite AH. Recent advances in medical diagnosis and treatment. BMJ 1938; 1: 1143-1146. Go to original source... Go to PubMed...
  26. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. AnnIntern Med 1994; 121(4): 289-300. Go to original source... Go to PubMed...
  27. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000; 343(21): 1520-1528. Go to original source... Go to PubMed...
  28. Varga Z, Kristova V, Kriska M. Kardiovaskulárne riziko nesteroidových antiflogistík - klinický dopad a možné mechanizmy. Klin Farmakol Farm 2011; 25(3): 131-136.
  29. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847. Go to PubMed...
  30. Gajdošík J, Brukkerová D, Kriška M, Svoreňová A. Poznáme dostatočne ochotu pacienta dodržiavať pokyny lekára? Prakt Lék 2007; 87(2): 103-107.
  31. Plantinga L, Grubbs V, Sarkar U, et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med 2011; 9: 423-430. Go to original source... Go to PubMed...
  32. Katzung BG, Masters SB, Trevor AJ (Eds). Basic and clinical pharmacology, 11th edition. McGraw-Hill, 2009: 1232.
  33. Tatro DS (Ed.). Drug interaction facts. Wolters Kluwer Health; 2010: 2192.
  34. Pannu N, Nadim NK. An overview of drug-induced acute kidney injury. Crit Care Med 2008; 36(Suppl.): 216-223. Go to original source... Go to PubMed...
  35. vanBoxtel CJ, Santoso B, Edwards IR (Eds.). Drug benefits and risks: international text book of clinical pharmacology. Chichester; Willey, 2001: 734.
  36. Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23(1): 138-141.
  37. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. The Oncologist 2006; 11: 694-703. Go to original source... Go to PubMed...
  38. Haľko J. Cytostatiká in Riziko liekov v medicínskej praxi. Kriška M (Ed.), Sap 2000: 265-285.
  39. Hardman JG, Limbird LE (Eds.). Goodman & Gilman´s The pharmacological basis of therapeutics - tenth edition. New York; McGraw-Hill, 2001: 2045.
  40. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334(2): 115-124. Go to original source... Go to PubMed...
  41. Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005; 16: 151-161. Go to original source... Go to PubMed...
  42. Condit PT, Chanes RE, Joel W. Renal toxicity of methotrexate. Cancer 1969; 23: 126-131. Go to original source...
  43. Rajec J, Mego M. Protinádorová liečba u pacientov s renálnou insuficienciou. Onkológia 2011; 6(2): 103-107.
  44. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4(12): 2029-2034. Go to original source... Go to PubMed...
  45. Svojanovský J, Ševela K, Souček M. Kontrastní látkou indukovaná nefropatie. Interní Med 2011; 13(5): 205-208.
  46. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008; 78(6): 743-750. Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.